Understand the scope of regulations of cell, tissue or gene therapy products in Singapore.
CTGTP are health products intended for use in humans for a therapeutic, preventive, palliative or diagnostic purpose. CTGTP can contain any of the following and achieves its primary intended action by pharmacological, immunological, physiological, metabolic or physical means:
Answer a few questions in our self-help tool to find out if your product is considered a CTGTP in Singapore. Let's go
The following products are NOT considered CTGTP:
We regulate CTGTP in Singapore under the Health Products Act (HPA) and its regulations, including the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021.
In Singapore, CTGTP are risk-stratified into two classes below:
Class 1 CTGTP (lower risk)
Class 2 CTGTP (higher risk)
Examples of Class 1 CTGTP:
Examples of Class 2 CTGTP:
^Minimally manipulated refers to any processing of the cell or tissue stated below that does not alter the cell's biological characteristics or functions, or the tissue's structural properties: cutting or sizing, grinding, shaping, centrifugation, soaking in an antibiotic or antimicrobial solution, sterilisation or irradiation, cell separation, concentration or purification, filtration, lyophilisation, freezing, cryopreservation or vitrification.
*Homologous use refers to using the CTGTP to repair, reconstruct, replace or supplement the cells or tissues of the recipient to perform the same basic function(s) as the original cells and tissue in the donor in the same anatomical or histological environment. E.g., bone grafts for orthopaedic indications.
Clinical trials involving Class 1 CTGTP are regulated under the Human Biomedical Research Act (HBRA) by the Ministry of Health. However, the manufacture, import and supply of CTGTP used as a clinical research material (CRM) in Singapore must comply with the regulations of CRM under the Health Products Act.
For Class 2 CTGTP, you may be required to apply for a Clinical Trial Authorisation or submit a Clinical Trial Notification to us before conducting the clinical trials in Singapore.
Before you can supply a CTGTP in Singapore, you will have to first:
Before you can import, manufacture and supply CTGTP in Singapore, you will need to first:
Submit a variation application to us when there is a change to your registered Class 2 CTGTP safety, efficacy or quality information.
You do not need to obtain prior approval from us before you advertise or promote your CTGTP.
However, you must comply with our regulations regarding advertising claims of CTGTP. Advertising and promotional messages should not contain misleading claims, lead to improper use of the product, or bring undue harm to the public.
If the CTGTP you are marketing poses a serious threat to health, causes death, or undesirable effects, you must report the adverse event to us within a given time frame.
As a dealer or product registrant, you are responsible for the safety, quality and efficacy of your CTGTP, and must know how to report and recall defective products that may potentially cause harm to patients or the public.
Regulatory overview
Class 1 CTGTP notification
Register a Class 2 CTGTP
Variation applications
Dealer's notice
Dealer's licensing and certification
Risk management plan requirements
Report adverse events
Report or recall defective products
Clinical trials
Product consultation
Advertisements and promotions
Certificate of a Pharmaceutical Product
Duties And Obligations
Guidance documents
Fees and turnaround time
Notified Class 1 CTGTP
Register of Class 2 CTGTP
Register of Licensed CTGTP Importers, Wholesalers and Manufacturers
CTGTP E-services